Asthma medication use during pregnancy, wheeze and estimated exposure to ambient nitrogen dioxide
Asthma affects 8-9% of pregnant women in the USA [1]. Since asthma exacerbations during pregnancy can lead to poor pulmonary function, hypoxia and other adverse health outcomes for the mother, fetus and neonate [2, 3], maintaining good control of asthma during pregnancy is recommended for the health...
Gespeichert in:
Veröffentlicht in: | The European respiratory journal 2015-02, Vol.45 (2), p.538-540 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Asthma affects 8-9% of pregnant women in the USA [1]. Since asthma exacerbations during pregnancy can lead to poor pulmonary function, hypoxia and other adverse health outcomes for the mother, fetus and neonate [2, 3], maintaining good control of asthma during pregnancy is recommended for the health of both mother and baby [4]. Reviews of the safety of asthma medication use during pregnancy suggest no or minimal effects on fetal growth and perinatal complications [4-6]. In spite of this, many pregnant women choose to reduce or stop their asthma medications [7]. |
---|---|
ISSN: | 0903-1936 1399-3003 |
DOI: | 10.1183/09031936.00161514 |